

**Ig usage data and statistics – January 2026**

**Overview**

Recent data and statistics on Ig use in Australia are presented below, providing a snapshot of Ig usage and trends in Australia. To accommodate data entry and reconciliation requirements, data are usually published approximately three months in arrears.


**Snapshot**

The snapshot provides an overview of the information that is further detailed in the graphs and tables that follow.


Patients	BloodSTAR
17,462 Total Patients January 2026	1,336 Authorisations in January 2026
866 New Patients who had Dispenses in January 2026	31,107 Dispense Events in January 2026
Product Issued	Ig Use
862,691 Grams Issued in January 2026	866,457 Grams Dispensed in January 2026
\$100 Million Expenditure in January 2026	250,635 g <b>Acquired hypogammaglobulinaemia — haematological malignancy or post HSCT</b> Grams Highest Medical Condition in January 2026

Ig use


**Year to date January 2026 - % variation year on year by jurisdiction.** This graph shows cumulative percentage changes in Ig issued, nationally and by jurisdiction, for the current financial year to date as compared to the same period in the previous financial year.



**Issues of Ig per 1,000 population by jurisdiction.** This graph shows the amount of Ig issued (grams) per 1,000 population nationally and by jurisdiction for the previous 3 months.




**Ig use by medical condition.** This graph shows the medical conditions which account for the highest use (grams dispensed) of Ig products.




**Patient use of intravenous Ig (IVIg) and subcutaneous Ig (SCIg) by medical condition.** This graph shows the number of patients who were dispensed SCIg or IVIg as a percentage of the total patients who received Ig (excluding normal human Ig (NHIg)) for a particular medical condition. The 5 medical conditions for which SCIg is available under the national blood arrangements are included. Note: Patients may use both IVIg and SCIg and are therefore counted in each category. As a result, totals may exceed 100%.

### Patient Use of IVIg and SCIg by Medical Condition July 2025 - January 2026




Product issued

Monthly expenditure on Ig. This graph shows the cost of Ig products issued over the last 9 months.




Monthly usage of Ig. This graph shows the amount of domestic and imported Ig products issued (grams) in the last 9 months.




**BloodSTAR**

**Patients.** This graph shows the total number of patients receiving Ig and the number of new patients over the last 9 months.



**Authorisations and dispense events.** This graph shows the number of new authorisation requests approved and the number of dispense events over the last 9 months.



Number of registered facilities	Number of registered SCIg approved facilities	Total number of registered users
1,235	123	30,209

**More information**

Annual reports on the issue and usage of immunoglobulin provide further information. For context and links, see: [Immunoglobulin usage and data | National Blood Authority](#).

In addition:

BloodSTAR Facility Administrators can access reports about their facility’s Ig usage through the reports function in BloodSTAR.

Jurisdictional Reports are available to Jurisdictional Blood Committee (JBC) representatives and their nominees. These provide information on the Ig dispensed for each State and Territory.

The NBA will also consider specific requests for data. All requests will be considered in line with the NBA’s Data and Information Governance Framework. More information, including about how to submit data requests, is available [here](#).